Back to Search
Start Over
801MO Efficacy and safety of a phase II study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML).
- Source :
-
Annals of Oncology . 2024 Supplement 2, Vol. 35, pS597-S597. 1p. - Publication Year :
- 2024
- Subjects :
- *CHRONIC leukemia
*AZACITIDINE
*ADULTS
*THERAPEUTICS
*SAFETY
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 35
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 179692248
- Full Text :
- https://doi.org/10.1016/j.annonc.2024.08.852